Bernard Barlaam

1.9k total citations
40 papers, 811 citations indexed

About

Bernard Barlaam is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Bernard Barlaam has authored 40 papers receiving a total of 811 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 17 papers in Organic Chemistry and 12 papers in Oncology. Recurrent topics in Bernard Barlaam's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Quinazolinone synthesis and applications (9 papers) and HER2/EGFR in Cancer Research (6 papers). Bernard Barlaam is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Quinazolinone synthesis and applications (9 papers) and HER2/EGFR in Cancer Research (6 papers). Bernard Barlaam collaborates with scholars based in United Kingdom, France and United States. Bernard Barlaam's co-authors include Christine Lambert‐van der Brempt, Donald Ogilvie, Richard Ducray, Jason G. Kettle, Peter Ballard, Samir Z. Zard, Jean Boivin, Douglas A. Campbell, Kurt G. Pike and Rose A. Maciewicz and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Bernard Barlaam

38 papers receiving 780 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernard Barlaam United Kingdom	17	448	306	256	101	63	40	811
Christine Lambert‐van der Brempt United Kingdom	11	520 1.2×	331 1.1×	243 0.9×	86 0.9×	63 1.0×	20	925
Zoltán Greff Hungary	13	1.0k 2.3×	225 0.7×	312 1.2×	107 1.1×	73 1.2×	21	1.5k
Benedict‐Tilman Berger Germany	19	590 1.3×	207 0.7×	197 0.8×	49 0.5×	68 1.1×	50	904
Céline Cano United Kingdom	21	834 1.9×	369 1.2×	387 1.5×	103 1.0×	51 0.8×	54	1.3k
Ruo W. Steensma United States	8	313 0.7×	148 0.5×	254 1.0×	117 1.2×	38 0.6×	9	740
Indrasish Ray Chaudhuri United States	16	642 1.4×	250 0.8×	244 1.0×	93 0.9×	113 1.8×	26	1.1k
Elena Casale Italy	15	602 1.3×	256 0.8×	253 1.0×	70 0.7×	91 1.4×	28	965
Surekha M. Zingde India	21	598 1.3×	612 2.0×	263 1.0×	57 0.6×	35 0.6×	63	1.2k
Arwin Aban United States	9	575 1.3×	211 0.7×	165 0.6×	48 0.5×	46 0.7×	13	748
Michael N. Greco United States	18	432 1.0×	489 1.6×	157 0.6×	135 1.3×	69 1.1×	32	967

Countries citing papers authored by Bernard Barlaam

Since Specialization

Citations

This map shows the geographic impact of Bernard Barlaam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Barlaam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Barlaam more than expected).

Fields of papers citing papers by Bernard Barlaam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Barlaam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Barlaam. The network helps show where Bernard Barlaam may publish in the future.

Co-authorship network of co-authors of Bernard Barlaam

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Barlaam. A scholar is included among the top collaborators of Bernard Barlaam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Barlaam. Bernard Barlaam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barlaam, Bernard, C. R. Diène, Eva M. Lenz, et al.. (2024). The Role of Intramolecular Reactions and Chemical Degradation in the Apparent Biotransformation Pathways of a Series of SYK Inhibitors. Drug Metabolism and Disposition. 52(7). 626–633.

Barlaam, Bernard, Scott Boiko, Scott Boyd, et al.. (2020). Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(22). 127523–127523. 3 indexed citations

Barlaam, Bernard, Elaine Cadogan, Andrew D. Campbell, et al.. (2018). Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors. ACS Medicinal Chemistry Letters. 9(8). 809–814. 19 indexed citations

Barlaam, Bernard, Sabina Cosulich, Martina Fitzek, et al.. (2017). Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors. Bioorganic & Medicinal Chemistry Letters. 27(13). 3030–3035. 5 indexed citations

Barlaam, Bernard, Sabina Cosulich, Sébastien L. Degorce, et al.. (2017). Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic & Medicinal Chemistry Letters. 27(9). 1949–1954. 3 indexed citations

Barlaam, Bernard, Sabina Cosulich, Sébastien L. Degorce, et al.. (2016). Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic & Medicinal Chemistry Letters. 26(9). 2318–2323. 6 indexed citations

Degorce, Sébastien L., Bernard Barlaam, Elaine Cadogan, et al.. (2016). Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase. Journal of Medicinal Chemistry. 59(13). 6281–6292. 55 indexed citations

Giordanetto, Fabrizio, et al.. (2014). Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents. Bioorganic & Medicinal Chemistry Letters. 24(16). 3936–3943. 19 indexed citations

Barlaam, Bernard, Sabina Cosulich, Sébastien L. Degorce, et al.. (2014). Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic & Medicinal Chemistry Letters. 24(16). 3928–3935. 17 indexed citations

10.

Hancox, Urs J., Sabina Cosulich, Hannah Dry, et al.. (2013). Abstract 3264: AZD8186: a potent selective inhibitor of PI3Kβ targeting PTEN-deficient tumours dependent on dysregulated PI3Kβ signalling.. Cancer Research. 73(8_Supplement). 3264–3264. 2 indexed citations

11.

Barlaam, Bernard, Judith Anderton, Peter Ballard, et al.. (2013). Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Medicinal Chemistry Letters. 4(8). 742–746. 31 indexed citations

12.

Barlaam, Bernard, Richard Ducray, Christine Lambert‐van der Brempt, et al.. (2011). Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series. Bioorganic & Medicinal Chemistry Letters. 21(8). 2207–2211. 26 indexed citations

13.

Hickinson, D. Mark, Teresa Klinowska, Georgina Speake, et al.. (2010). AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer. Clinical Cancer Research. 16(4). 1159–1169. 95 indexed citations

14.

Bardelle, Catherine, Bernard Barlaam, Nigel Brooks, et al.. (2010). Inhibitors of the tyrosine kinase EphB4. Part 3: Identification of non-benzodioxole-based kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(21). 6242–6245. 30 indexed citations

15.

Barlaam, Bernard, et al.. (2009). Insight into the Complexation Mode of Bis(nitrilotriacetic acid) (NTA) Ligands with Ni²⁺ Involved in the Labeling of Histidine‐Tagged Proteins. Chemistry - A European Journal. 15(46). 12689–12701. 12 indexed citations

16.

Barlaam, Bernard, David Acton, Peter Ballard, et al.. (2008). Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 18(6). 1799–1803. 10 indexed citations

17.

Ducray, Richard, et al.. (2007). Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(3). 959–962. 70 indexed citations

18.

Ballard, Peter, Bernard Barlaam, Robert H. Bradbury, et al.. (2007). Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 17(22). 6326–6329. 23 indexed citations

19.

Barlaam, Bernard, Peter Ballard, Robert H. Bradbury, et al.. (2007). A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 18(2). 674–678. 18 indexed citations

20.

Barlaam, Bernard, Tim Green, Laurent Hennequin, et al.. (2005). New heterocyclic analogues of 4-(2-chloro-5-methoxyanilino)quinazolines as potent and selective c-Src kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(24). 5446–5449. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact